ONCOINVENT ASA (ONCIN.OL) Stock Price, Forecast & Analysis
OSL:ONCIN • NO0013711713
ONCIN.OL Key Statistics, Chart & Performance
The current stock price of ONCIN.OL is 42.4 NOK. In the past month the price decreased by -1.37%.
ONCIN.OL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ONCIN.OL.
ONCIN.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ONCIN.OL. ONCIN.OL has a great financial health rating, but its profitability evaluates not so good.
ONCIN.OL Financial Highlights
Over the last trailing twelve months ONCIN.OL reported a non-GAAP Earnings per Share(EPS) of -48.72. The EPS increased by 70.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -160.55% | ||
| ROE | -207.87% | ||
| Debt/Equity | 0 |
ONCIN.OL Forecast & Estimates
9 analysts have analysed ONCIN.OL and the average price target is 2.75 NOK. This implies a price decrease of -93.5% is expected in the next year compared to the current price of 42.4.
For the next year, analysts expect an EPS growth of 97.38% and a revenue growth 6400% for ONCIN.OL
ONCIN.OL Ownership
ONCIN.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SAN | SANOFI | 9.72 | 198.536B | ||
| 1SAN | SANOFI | 9.72 | 198.488B | ||
| SNW | SANOFI | 9.72 | 198.464B | ||
| MRK | MERCK KGAA | 14.86 | 55.543B | ||
| UNC | UCB SA | 26.34 | 52.693B | ||
| UCB | UCB SA | 24.53 | 49.075B | ||
| 1BAYN | BAYER AG-REG | 8.6 | 41.291B | ||
| BAYN | BAYER AG-REG | 8.6 | 41.272B | ||
| IPN | IPSEN | 14.47 | 13.837B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.69 | 10.126B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About ONCIN.OL
Company Profile
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. The firm is based in Bergen, Norway with a subsidiary in Oxford, UK.
Company Info
ONCOINVENT ASA
Gullhaugveien 7
Oslo OSLO NO
Employees: 36
Phone: 4722183305
ONCOINVENT ASA / ONCIN.OL FAQ
What does ONCOINVENT ASA do?
Oncoinvent ASA engages in the development of biopharmaceutical product for cancer therapy. The company is headquartered in Oslo, Oslo and currently employs 7 full-time employees. The company went IPO on 2017-04-07. The firm's business portfolio comprises such development stage products as oral axillary lymphoscintigraphy (AXL) which is a tyrosine kinase target that mediates aggressive disease. Under normal healthy physiological conditions, there is low expression of AXL. However, in aggressive diseases, such as cancer and severe respiratory infections, AXL signaling is upregulated in response to hypoxia, inflammation, cellular stress and drug treatment. The firm's flagship product is BGB324, is a selective, potent and orally bio-available small molecule AXL inhibitor in Phase II clinical trials in cancer indications and COVID-19. The firm is based in Bergen, Norway with a subsidiary in Oxford, UK.
What is the stock price of ONCOINVENT ASA today?
The current stock price of ONCIN.OL is 42.4 NOK. The price decreased by -1.52% in the last trading session.
What is the dividend status of ONCOINVENT ASA?
ONCIN.OL does not pay a dividend.
What is the ChartMill rating of ONCOINVENT ASA stock?
ONCIN.OL has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of ONCOINVENT ASA (ONCIN.OL)?
ONCOINVENT ASA (ONCIN.OL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-48.72).
Can you provide the market cap for ONCOINVENT ASA?
ONCOINVENT ASA (ONCIN.OL) has a market capitalization of 189.95M NOK. This makes ONCIN.OL a Micro Cap stock.